Skip to main content

Table 3 Multivariate analyses of AML patients receiving chemotherapy only and allo-HSCT based on left-truncated Cox model

From: Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation

Variable

No. of patients

HR (95% CI)

P value

Relapse

 Therapy

  Allo-HSCT

45

1.00

 

  Chemotherapy only

43

11.49 (4.43–29.82)

<0.001

 WT1 transcript levela

  High

48

1.00

 

  Low

40

3.53 (1.64–7.62)

0.001

 MRD test resultb

  Negative

53

1.00

 

  Positive

35

2.30 (1.06–4.97)

0.034

Treatment failure

 Therapy

  Allo-HSCT

45

1.00

 

  Chemotherapy only

43

5.85 (2.75–12.44)

<0.001

 WT1 transcript level

  High

48

1.00

 

  Low

40

3.71 (1.82–7.56)

<0.001

 MRD test result

  Negative

53

1.00

 

  Positive

35

2.33 (1.17–4.64)

0.016

Mortality

 Therapy

  Allo-HSCT

45

1.00

 

  Chemotherapy only

43

4.34 (1.98–9.53)

<0.001

 WT1 transcript level

  High

48

1.00

 

  Low

40

3.50 (1.56–7.82)

0.002

 MRD test result

  Negative

53

1.00

 

  Positive

35

2.32 (1.09–4.97)

0.030

  1. HR hazard ratio, CI confidence interval, WT1 Wilm tumor gene-1, MRD measureable residual disease, RUNX1-RUNX1T1 runt-related transcription factor 1-RUNX1 translocation partner 1
  2. aPatients with WT1 transcript levels ≤5.0% and >5.0% at diagnosis were characterized as having low and high WT1 transcript levels, respectively
  3. bA less than and no less than 3-log reduction in RUNX1-RUNX1T1 transcript level compared to baseline (>0.4% and ≤0.4%) after the second cycle of consolidation chemotherapy were defined as positive and negative MRD test results, respectively